ArticleCancer2013
Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
Article in Cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 41 citations in OpenAlex.
- Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia.Blood · 2018Trial
- Evaluating the patterns of use and safety of lenalidomide treatment in myelodysplastic syndromes: a European, observational multi-registry study.Therapeutic advances in drug safety · 2026Article
- Article
- Management of the Older Patient with Myelodysplastic Syndrome.Drugs & aging · 2021Review
- Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States.Blood advances · 2020Article
- Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.Cell proliferation · 2020Article
- The Role of Real-World Evidence in UK Reimbursement: Case Study of Lenalidomide in Myelodysplastic Syndrome Deletion 5q.PharmacoEconomics - open · 2019Article
- Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy.Oncotarget · 2017Article
- Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study.PloS one · 2017Article
- Article
- Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes.Journal of comparative effectiveness research · 2015Article
- Polish experience of lenalidomide in the treatment of lower risk myelodysplastic syndrome with isolated del(5q).BMC cancer · 2015Article
- Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes.Journal of blood medicine · 2015Review
- Acute myeloid leukemia and myelodysplastic syndromes in older adults.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Review
- Beyond hypomethylating agents failure in patients with myelodysplastic syndromes.Current opinion in hematology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundLenalidomide is approved for the treatment of anemia with transfusion dependence (TD) in patients with lower-risk myelodysplastic syndrome (MDS) with 5q deletion (del5q-MDS), but its "real-life" use and effect on transfusion needs are unclear. In the current study, the authors examined its use in the Medicare population.
methodsPatients with MDS who were enrolled in Medicare Parts A, B, and D were identified using International Classification of Diseases 9-Clinical Modification (ICD-9) codes from 100% Medicare claims from 2006 through 2008. Patients were followed until the end of the study or death. Claims were used to determine time to initiation of lenalidomide, daily dose, duration, and other MDS therapies. Transfusion status was defined each week based on transfusion use in rolling 8-week period: TD, required transfusions during 2 weeks, separated by ≥ 3 weeks; transfusion user (TU), 1 transfusion; and transfusion independence (TI), no transfusions.
resultsA total of 753 of 23,855 patients (3.2%) received lenalidomide, including 31% of 470 patients with del5q-MDS. At the time of lenalidomide initiation, 33% of patients were TD, 31% were TU, and 36% were TI. The median time to lenalidomide initiation was shorter for patients with del5q-MDS than for other lower-risk patients (8 weeks vs 20 weeks; P < .01). The percentage of patients with del5q-MDS receiving lenalidomide increased over time. Lenalidomide initiation was found to be negatively associated with older age and baseline diabetes, stroke, and renal disease. During the observation period, 44% of TU/TD patients (53% of the patients with del5q-MDS) achieved reductions in transfusion use; among TD patients receiving ≥ 3 cycles, 77% reduced their transfusion use and 40% achieved TI.
conclusionsTo the authors' knowledge, the current study is the first report of lenalidomide use in a large Medicare-enrolled population with MDS. Reductions in transfusion rates were overall consistent with data from clinical trials. Response rates were higher when ≥ 3 lenalidomide cycles were received.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.